細胞番号 : 細胞名
RCB1191 : 5637
update : 2022/07/13
|
| 細胞特性(Comment:英) | Described to produce SCF, IL-1, IL-3, IL-6, G-CSF, GM-CSF, etc. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 35 prior to order. |
| 細胞特性(日) | SCF, IL-1, IL-3, IL-6, G-CSF, GM-CSF, etc.を作りだすと言われているヒト膀胱癌細胞。DSMZとの交換細胞株。使用条件等が DSMZによって随時変更となる可能性があります。ご購入前に、ACC 35 を必ずご参照ください。 |
| 細胞特性(寄託者記述:英) | |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | 1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 35 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| 使用条件(日) | 1) 基礎的研究につきましては、使用制限はありません。しかし、使用条件等がDSMZによって随時変更となる可能性があるので、購入前に、ACC 35を必ず参照すること。2) 商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
DSMZ
|
| 寄託日 |
1995
|
| 動物種 |
_human
< Mammals
|
| 属名 |
Homo
|
| 種名 |
sapiens
|
| 性別 |
Male
|
| 齢 |
68 years
|
| 採取組織 |
bladder
|
| 病名 |
bladder carcinoma
|
| 細胞分類 |
cancer
|
| 入手歴 |
overseas
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_0126
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
| 培地 |
|
RPMI1640 + 10% FBS
|
| 抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin
|
|
継代密度 |
|
1 : 8 split
|
| 継代・培地交換頻度 |
|
Subculture : 2 times/week
|
| 培養最適温度 |
|
37
℃
|
| 二酸化炭素濃度 |
|
5
%
|
| 凍結培地 |
|
Medium + 10% DMSO
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ |
|
(-)
|
| アイソザイム検査 |
|
LD, NP
|
| 染色体検査 |
|
50-67(50) : /59(5),60(5),61(4),62(3),63(5),64(9)/
|
| 個体識別検査 |
|
OK
|
| 画像情報 |
寄託時情報 | ロット情報 |
|
|
|
| 文献情報 |
Reference(英) |
11件
|
| Reference(日) |
0件
|
| 利用者成果(英) |
6件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
4954
Quentmeier H, Zaborski M, Drexler HG.
The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines.
Leuk Res
1997
21(4):343-50
PubMed ID: 9150352
DOI: 10.1016/s0145-2126(96)00132-4
|
|
2040
Bailly JD, Pourquier P, Jaffrézou JP, Duchayne E, Cassar G, Bordier C, Laurent G.
Effect of 5637-conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF-dependent leukemic myeloid cell line
Leukemia
1995
9(10):1718-25
PubMed ID: 7564516
|
|
4953
Kaashoek JG, Mout R, Falkenburg JH, Willemze R, Fibbe WE, Landegent JE.
Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure.
Lymphokine Cytokine Res
1991
10(3):231-5
PubMed ID: 1883917
|
|
2039
Borinaga AM, Millar BC, Bell JB, Joffe JK, Millar JL, Gooding R, Riches P, McElwain TJ.
Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro
Br J Haematol
1990
76(4):476-83
PubMed ID: 2265109
DOI: 10.1111/j.1365-2141.1990.tb07903.x
|
|
2038
Tennant GB, Jacobs A.
Effect of 5637-conditioned medium on peripheral blood granulocyte-macrophage progenitors in normal subjects and patients with the myelodysplastic syndrome
Leuk Res
1989
385-9
PubMed ID: 2787448
DOI: 10.1016/0145-2126(89)90078-7
|
|
2036
Miyauchi J, Kelleher CA, Yang YC, Wong GG, Clark SC, Minden MD, Minkin S, McCulloch EA.
The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture.
Blood
1987
70(3):657-63
PubMed ID: 3304459
|
|
2037
Asano Y, Shibuya T, Okamura S, Morioka E, Taniguchi S, Niho Y.
Synergism of leukemic blast growth factors in medium conditioned by human bladder carcinoma cell line 5637.
Int J Cell Cloning
1987
5(6):504-10
PubMed ID: 3480913
DOI: 10.1002/stem.5530050608
|
|
2035
Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, Moore MA.
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
Proc Natl Acad Sci U S A
1985
82(5):1526-30
PubMed ID: 3871951
DOI: 10.1073/pnas.82.5.1526
|
|
5464
Welte K, Platzer E, Gabrilove JL, Lu L, Levi E, Polivka A, Mertelsmann R, Moore MA.
Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
Haematol Blood Transfus
1985
29:398-401
PubMed ID: 3875526
DOI: 10.1007/978-3-642-70385-0_82
|
|
4956
Myers CD, Katz FE, Joshi G, Millar JL.
A cell line secreting stimulating factors for CFU-GEMM culture.
Blood
1984
64(1):152-5
PubMed ID: 6733267
|
|
3355
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl Cancer Inst Monogr
1978
49:5-9.
PubMed ID: 571047
|
| 利用者成果(英) |
|
16352
Shimizu R, Ohira T, Yagyu T, Yumioka T, Yamaguchi N, Iwamoto H, Morizane S, Hikita K, Honda M, Takenaka A, Kugoh H.
Activation of PPARγ in bladder cancer via introduction of the long arm of human chromosome 9
Oncol Lett
2022
23(3):92
PubMed ID: 35154423
DOI: 10.3892/ol.2022.13212
|
|
13329
Matsumura E, Kosuge N, Nakanishi S, Suda T, Sugawa A, Fujimura T, Miyagi R, Yoshimi N, Saito S.
Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.
Tohoku J Exp Med
2020
PubMed ID: 33162487
DOI: 10.1620/tjem.252.225
|
|
6920
Psurski M, Łupicka-Słowik A, Adamczyk-Woźniak A, Wietrzyk J, Sporzyński A.
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells.
Invest New Drugs
2019
37(1):35-46
PubMed ID: 29779163
DOI: 10.1007/s10637-018-0611-z
|
|
14268
Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI.
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer
Int J Oncol
2017
51(2):579-586
PubMed ID: 28714514
DOI: 10.3892/ijo.2017.4031
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
2708
Nanda K, Miyoshi N, Nakamura Y, Shimoji Y, Tamura Y, Nishikawa Y, Uenakai K, Kohno H, Tanaka T.
Extract of vinegar "Kurosu" from unpolished rice inhibits the proliferation of human cancer cells.
J. Exp. Clin. Cancer Res.
2004
23:69-75
PubMed ID: 15149153
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
